脱发的患者如今越来越多,脱发的治疗方法也是各种各样,本人在国外论坛中发现了一个特殊的脱发治疗案例,这样的病例虽然很少见,但也并非不存在。下面就来和大家分享一下,希望对大家有所帮助,
我的病人是一位来自中国46岁的男性,在2009年10月12日被诊断患有秃头症与肠癌。在我们起初遇见他时,她的CEA是4,030纳克/毫升。
2009年10月28日,他开始接受了名为FOLFOX的化学治疗法,每两个星期进行一次,这种另类的疗法中包裹每三个星期摄入3,000mg的维生素C。另外,在2009年12月,病人开始每天摄入8g的fucoidan(岩藻依聚糖)。
FOLFOX化学疗法对于病人的副作用很低。另外,据报告显示,在病人接受FOLFOX治疗的12星期中,脱发的迹象明显有了好转。不幸的是,病人的肿瘤仍然在进行扩散,在2010年的1月,病人的CEA到达了7,900ng/ml 。它的肿瘤医生开始对他的化学治疗药物进行调整,他开始服用cetuximab+FOLFIRI(爱必妥+亚叶酸钙)。随后,他出现一些明显的副作用,例如腹泻,恶心,皮肤出诊的症状。
在2010年2月,他的肠癌对于新的化学治疗药物产生了良好反应。他的CEA在四个星期中就降到了296ng/ml。直到三月份,在这两个月里,他的CEA又下降到了259ng/ml。2010年的四月,在化疗进行后第三个月,我们可以清晰的从病人的CT中看到,肿瘤的大小已经缩小至之前的十分之一,以及开始普遍的钙化。除此之外,脱发迹象也有了一定的好转。直到七月末,病人的身体状况依然非常乐观。
Successful treatment of chemotherapy-inducedalopeciawith laser cap: a case report
The patient is a 46-year-old male of Chinesedecent diagnosed with stage iv colon cancer on October 12, 2009. His CEA at thetime of discovery was 4,030ng/ml.
FOLFOX(5-fu,folinic acid,oxaloplatin) chemotherapy every two weeks was started on October28.2009 alternative therapy included fermented wheat germ extract(avemar) and high-dose IV Vitamin C (3,000mg IV,3 times per week) beginning inthe same mouth and 8g/day of fucoidan from focus vesiculosis
beginning in early December 2009.
The patient had minimal side effects fromthe FOLFOX chemotherapy regimen, report no G1 discomforts, and had no noticeablehair loss during his 12 weeks of FOLFOX. Unfortunately ,the patients tumors did notrespond to the chemo regimen, and his CEA reached 7,900ng/ml by January 2010.His oncologist switched his chemo regiment to cetuximab +FOLFIRI(5-FU,folinicacid, irinotecan)while his alternative therapies remained the same.Under this new regiment, he experiencedsignificant side effects including diarrhea, nausea, skin eruptions, and,within several weeks, significant hair loss.
His colon cancer responded to the new chemoregiment, and his CEA dropped to 296ng/ml in 4 weeks(February 2010) and259ng/ml in 2 months (march 2010). The patients CT after 3 months of chemo ( april2010) showed significant reduction of tumor size (<1/10 of the volume at thetime of discovery) and widespread calcification. His fucoidan regimen waschanged to a 50/50 mix of focus vesiculous and undaria pinnatifida at the endof july also showed reductions in tumor size and count. As of july 31,2010, thepatient is still on the same protocol.
|